Features of complex therapy of hemorrhagic fever with renal syndrome against the background of liver damage

Aim. To evaluate the effectiveness of hepatoprotective support in patients with hemorrhagic fever with renal syndrome (HFRS) with cytolytic syndrome by using the combined drug Remaxol®. Materials and methods. 60 patients with HFRS were examined: 43 (71.7%) men, 17 (28.3%) women, the average age of patients was 41.4±2.3 years. The subjects were divided into 2 groups (30 people each). Study design: open, randomized, comparative. Results. The analysis of the use of the drug Remaxol® was carried out as a means of hepatotropic support for patients with HFRS with liver damage. When evaluating the dynamics of clinical and laboratory parameters characterizing liver functionality in 2 groups of patients receiving intravenous infusions of Remaxol® (400.0 ml) or active placebo (400.0 ml 0.9% sodium chloride solution) for 10 days, it was shown that the use of Remaxol® as a hepatoprotector in the complex treatment of patients HFRS with cytolysis syndrome contributes to the dynamic stabilization of biochemical parameters of liver function and normalization of its size. Conclusion. The use of Remaxol® as part of the complex pathogenetic therapy of patients with HFRS with liver damage makes it possible to accelerate the disappearance of cytolytic syndrome, as well as laboratory indicators of cholestasis. The good tolerability of Remaxol® and the absence of significant side effects make it possible to recommend its wide use in this cohort of patients.